D 12

Banoxantrone D12 (AQ4N D12) is the deuterium-labeled form of Banoxantrone, a bioreductive agent that can be metabolically converted to AQ4, a stable compound with DNA affinity and topoisomerase II inhibition properties.

Topiramate D12 is a deuterium labeled Topiramate. Topiramate is an agent of broad-spectrum antiepileptic. Topiramate is an antagonist of GluR5 receptor.

Banoxantrone D12 (AQ4N D12) dihydrochloride is the deuterium-labeled Banoxantrone. Banoxantrone is a bioreductive agent that can be reduced to a stable, DNA-affinity compound AQ4, which is a topoisomerase II inhibitor.

3-Hydroxyoctanoic Acid-d12 是 3-Hydroxyoctanoic Acid 的氘代物。

Vancomycin-d12 TFA 是 Vancomycin TFA 的氘代化合物。Vancomycin TFA 的 CAS 号为 1404-90-6。Vancomycin 是一种抗生素，用于通过阻止细菌生长来治疗严重的细菌感染。它还改变细胞膜的渗透性并选择性地抑制核糖核酸的合成。

Tetramethylpyrazine-d12 是 Tetramethylpyrazine 的氘代化合物。Tetramethylpyrazine 的 CAS 号为 1124-11-4。Tetramethylpyrazine 是从Ligusticum wallichii中提取的一种烷基吡嗪，常在薯条、面包、茶、乳制品、豆制品等食物中作为香精。它对大鼠具有潜在的抗神经和抗炎活性。

Chrysene-d12 是 Chrysene 的氘代化合物。Chrysene 的 CAS 号为 218-01-9。Chrysene 是高分子量 (HMW) 多环芳烃，有极强的顽固性和致癌性。

Perylene-d12 是 Perylene 的氘代化合物。Perylene 的 CAS 号为 198-55-0。

Chrysene-d12 (Standard) 是 Chrysene-d12 的标准品，适用于定量分析、质量控制及生化实验等相关研究。Chrysene-d12 是 Chrysene 的氘代化合物。Chrysene 的 CAS 号为 218-01-9。Chrysene 是高分子量 (HMW) 多环芳烃，有极强的顽固性和致癌性。

Perylene-d12 (Standard) 是 Perylene-d12 的标准品，适用于定量分析、质量控制及生化实验等相关研究。Perylene-d12 是 Perylene 的氘代化合物。Perylene 的 CAS 号为 198-55-0。

Benzo[k]fluoranthene-d12 是 Benzo[k]fluoranthene 的氘代化合物。Benzo[k]fluoranthene 的 CAS 号为 207-08-9。

D-(+)-Trehalose-13C12为D-(+)-Trehalose的13C同位素标记版，后者作为食品成分和赋形剂在广泛应用中。

KRASG12D-IN-3-d3是KRASG12D-IN-3的氘代物。KRASG12D-IN-3 (compound Z1084) 是一种 KRASG12D 抑制剂，具有口服生物活性，可有效抑制肿瘤细胞AGS和AsPC-1的生长过程，IC50 值分别为 0.38 nM 和 1.23 nM。

N1,N12-Diacetylspermine-d6 (DiAcSpm-d6) 是 N1,N12-Diacetylspermine 的氘代物。

Exatecanintermediate 12-d5是Exatecanintermediate 12的氘标记版本。Exatecan intermediate 12是合成ADC毒素Exatecan的关键中间体，并可用于ADC化合物的制备。

18-Hydroxycorticosterone-d4 是 18-Hydroxycorticosterone 的氘代化合物。18-Hydroxycorticosterone 的 CAS 号为 561-65-9。

WNK-IN-12 is an effective, selective, and orally active WNK1 kinase inhibitor.

Aflatoxin B2-13C17(AFB2-13C17) is intended for use as an internal standard for the quantification of AFB2by GC- or LC-MS. AFB2is a mycotoxin that has been found inA. terricola.1It induces hepatic autophagy and apoptosis in broiler chickens when administered at doses of 0.2, 0.4, and 0.8 mg/kg.2AFB2(0.5 and 1 mg/animal) also induces parenchymal cell hyperplasia in rats.3 1.Moubasher, A.H., el-Kady, I.A., and Shoriet, A.Toxigenic Aspergilli isolated from different sources in EgyptAnn. Nutr. Aliment.31(4-6)607-615(1977) 2.Chen, B., Li, D., Li, M., et al.Induction of mitochondria-mediated apoptosis and PI3K/Akt/mTOR-mediated autophagy by aflatoxin B2 in hepatocytes of broilersOncotarget7(51)84989-84998(2016) 3.Wogan, G.N., Edwards, G.S., and Newberne, P.M.Structure-activity relationships in toxicity and carcinogenicity of aflatoxins and analogsCancer Res.31(12)1936-1942(1971)

Zonisamide-13C2,15N is intended for use as an internal standard for the quantification of zonisamide by GC- or LC-MS. Zonisamide is an antiepileptic agent.1 It selectively inhibits the repeated firing of sodium channels (IC50 = 2 μg/ml) in mouse embryo spinal cord neurons and inhibits spontaneous channel firing when used at concentrations greater than 10 μg/ml.2 In rat cerebral cortex neurons, zonisamide (1-1,000 μM) inhibits T-type calcium channels with a maximum reduction of 60% of the calcium current.3 Zonisamide inhibits H. pylori recombinant carbonic anhydrase (CA) and the human CA isoforms I, II, and V with Ki values of 218, 56, 35, and 21 nM, respectively.4,5 In mice, it has anticonvulsant activity against maximal electroshock seizure (MES) and pentylenetetrazole-induced maximal, but not minimal, seizures (ED50s = 19.6, 9.3, and >500 mg/kg, respectively). Zonisamide (40 mg/kg, p.o.) prevents MPTP-induced decreases in the levels of dopamine , but not homovanillic acid or dihydroxyphenyl acetic acid , and increases MPTP-induced decreases in the dopamine turnover rate in mouse striatum in a model of Parkinson's disease.6 Formulations containing zonisamide have been used in the treatment of partial seizures in adults with epilepsy. |1. Masuda, Y., Ishizaki, M., and Shimizu, M. Zonisamide: Pharmacology and clinical efficacy in epilepsy. CNS Drug Rev. 4(4), 341-360 (1998).|2. Rock, D.M., Macdonald, R.L., and Taylor, C.P. Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD 810, CI 912), a novel anticonvulsant. Epilepsy Res. 3(2), 138-143 (1989).|3. Suzuki, S., Kawakami, K., Nishimura, S., et al. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res. 12(1), 21-27 (1992).|4. Nishimori, I., Vullo, D., Minakuchi, T., et al. Carbonic anhydrase inhibitors: Cloning and sulfonamide inhibition studies of a carboxyterminal truncated α-carbonic anhydrase from Helicobacter pylori. Bioorg. Med. Chem. Lett. 16(8), 2182-2188 (2006).|5. De Simone, G., Di Fiore, A., Menchise, V., et al. Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: Solution and X-ray crystallographic studies. Bioorg. Med. Chem. Lett. 15(9), 2315-2320 (2005).|6. Yabe, H., Choudhury, M.E., Kubo, M., et al. Zonisamide increases dopamine turnover in the striatum of mice and common marmosets treated with MPTP. J. Pharmacol. Sci. 110(1), 64-68 (2009).